How does Sitagliptin impact inflammation markers in patients with comorbidities, and what are the broader implications for systemic health?
Sunil JoshiExplorer
How does Sitagliptin impact inflammation markers in patients with comorbidities?
Share
Sitagliptin reduces inflammation markers like CRP and IL-6 in diabetic patients, potentially lowering cardiovascular risks.